We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+10.89%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$338M
AUM Growth
+$104M
(+44%)
Cap. Flow
+$99.8M
Cap. Flow
% of AUM
29.5%
Top 10 Holdings %
Top 10 Hldgs %
45.78%
Holding
65
New
30
Increased
14
Reduced
12
Closed
7
Top Buys
| 1 |
TG Therapeutics
TGTX
|
+$16.7M |
| 2 |
Pfizer
PFE
|
+$8.64M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$8.47M |
| 4 |
Johnson & Johnson
JNJ
|
+$8.07M |
| 5 |
uniQure
QURE
|
+$7.87M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$25.2M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$13.3M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$10.9M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$7.81M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$6.02M |
Sector Composition
| 1 | Healthcare | 78.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Geron
GERN
$924M
| $977K | 0.29% |
+450,000
| New | +$1.28M |
|
52
X4 Pharmaceuticals
XFOR
$360M
| $740K | 0.22% |
28,333
-5,000
| -15% | -$147K |
|
|
SWTX
53
DELISTED
SpringWorks Therapeutics
SWTX
| $710K | 0.21% |
+27,578
| New | +$806K |
|
|
KZR
54
DELISTED
Kezar Life Sciences
KZR
| $548K | 0.16% |
17,500
-16,491
| -49% | -$954K |
|
|
KYNB
55
Kyntra Bio
KYNB
$29.3M
| $494K | 0.15% |
+1,060
| New | +$561K |
|
|
IMGN
56
DELISTED
Immunogen Inc
IMGN
| $480K | 0.14% |
+124,977
| New | +$533K |
|
57
BridgeBio Pharma
BBIO
$15.9B
| $415K | 0.12% |
+25,000
| New | +$292K |
|
58
Vanda Pharmaceuticals
VNDA
$327M
| $85K | 0.03% |
+12,500
| New | +$87.9K |
|
|
BPMC
59
DELISTED
Blueprint Medicines
BPMC
| – | – |
-20,000
| Closed | -$876K |
|
60
Design Therapeutics
DSGN
$785M
| – | – |
-82,853
| Closed | -$850K |
|
|
61
Invesco QQQ Trust
QQQ
$466B
| – | – |
-50,000
| Closed | -$13.3M |
|
|
RAPT
62
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-15,625
| Closed | -$2.48M |
|
63
Spyre Therapeutics
SYRE
$8.7B
| – | – |
-32,000
| Closed | -$360K |
|
|
SGEN
64
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-85,000
| Closed | -$10.9M |
|
|
PRVB
65
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| – | – |
-400,000
| Closed | -$4.23M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2023 Portfolio in Review
As of Q1 2023, Ghost Tree Capital held 65 positions worth $338M, up 44% from $234M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Ghost Tree Capital deployed $99.8M of net new capital in Q1 2023, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was TG Therapeutics: 1,100,000 shares worth $16.5M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $25.2M trimmed.
- Ghost Tree Capital's largest Q1 2023 buy was TG Therapeutics: 1,100,000 shares worth $16.5M.
- Ghost Tree Capital added most to Akero Therapeutics in Q1 2023, an estimated $8.47M increase.
- Ghost Tree Capital's biggest Q1 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $25.2M.
- Ghost Tree Capital fully exited Invesco QQQ Trust in Q1 2023, selling an estimated $13.3M.
- Ghost Tree Capital's ten largest holdings make up 46% of its $338M portfolio in Q1 2023.
- Ghost Tree Capital opened 30 new positions and closed 7 in Q1 2023.
- Ghost Tree Capital's portfolio value rose 44% quarter-over-quarter to $338M.
Based on Ghost Tree Capital's 13F filing for Q1 2023, filed 15 May 2023.